CTIC CTI BioPharma Corp.

4.18
+0.01  (0%)
Previous Close 4.17
Open 4.15
Price To book 0.00
Market Cap 117.23M
Shares 28,045,000
Volume 14,365
Short Ratio 12.29
Av. Daily Volume 73,073

SEC filingsSee all SEC filings

  1. 8-K - Current report 17874651
  2. CT ORDER - Confidential treatment order 17859553
  3. 8-K - Current report 17849204
  4. CT ORDER - Confidential treatment order 17820868
  5. CT ORDER - Confidential treatment order 17820749

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Top-line data from confirmatory trial required for full EMA approval due by end of 2017.
PIXUVRI
B-cell non-Hodgkin lymphoma
PERSIST-2 data released August 2016. One of two primary endpoints met. Announced January 5, 2017 removal of clinical hold. Additional trial to commence 2Q 2017.
Pacritinib - PAC203
Myelofibrosis
Phase 3 trial potentially in the pipeline.
Tosedostat
Older patients with AML or high-risk myelodysplastic syndrome (MDS) - cancer
Phase 3 - noted July 2016 that unlikely to have survival benefit
OPAXIO
Ovarian cancer

Latest News

  1. ETFs with exposure to CTI BioPharma Corp. : May 25, 2017
  2. Edited Transcript of CTIC earnings conference call or presentation 3-May-17 8:30pm GMT
  3. CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q1, 2017 By the Numbers : May 5, 2017
  4. CTI BioPharma reports 1Q loss
  5. CTI BioPharma Reports First Quarter 2017 Financial Results
  6. CTI BioPharma to Report First Quarter 2017 Financial Results on May 3, 2017
  7. ETFs with exposure to CTI BioPharma Corp. : April 26, 2017
  8. Servier and CTI BioPharma Expand License and Collaboration Agreement to Develop and Commercialize PIXUVRI®
  9. Edited Transcript of CTIC earnings conference call or presentation 2-Mar-17 9:30pm GMT
  10. ETFs with exposure to CTI BioPharma Corp. : March 30, 2017
  11. CTI BioPharma Corp. :CTIC-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
  12. CTI BioPharma to Present at the 29th Annual ROTH Conference
  13. CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results
  14. CTI BioPharma hires new CEO
  15. CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO
  16. CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
  17. CTI BioPharma to Present at the BIO CEO & Investor Conference
  18. CTI BioPharma Appoints Leading BioPharma Executive Michael Metzger To Board Of Directors

SEC Filings

  1. 8-K - Current report 17874651
  2. CT ORDER - Confidential treatment order 17859553
  3. 8-K - Current report 17849204
  4. CT ORDER - Confidential treatment order 17820868
  5. CT ORDER - Confidential treatment order 17820749
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 17810329
  7. 8-K - Current report 17809256
  8. 8-K - Current report 17809183
  9. 8-K - Current report 17790292
  10. 8-K - Current report 17781415